A share price of Amylyx Pharmaceuticals Inc [AMLX] is currently trading at $5.31, up 8.37%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AMLX shares have gain 11.09% over the last week, with a monthly amount glided 65.94%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] stock has seen the most recent analyst activity on October 23, 2024, when BofA Securities upgraded its rating to a Buy and also boosted its price target to $10 from $4.20. Previously, Mizuho downgraded its rating to Neutral on March 18, 2024, and dropped its price target to $4. On March 11, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $4 on the stock. Leerink Partners downgraded its rating to a Market Perform and decreased its price target to $4 on March 11, 2024. Goldman downgraded its rating to a Neutral. Evercore ISI downgraded its rating to In-line for this stock on March 08, 2024. In a note dated January 03, 2024, Robert W. Baird initiated an Outperform rating and provided a target price of $37 on this stock.
Amylyx Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $1.58 and $19.95. Currently, Wall Street analysts expect the stock to reach $5.33 within the next 12 months. Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] shares were valued at $5.31 at the most recent close of the market. An investor can expect a potential return of 0.38% based on the average AMLX price forecast.
Analyzing the AMLX fundamentals
Trailing Twelve Months sales for Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] were 298.76M which represents -101.04% decline. Gross Profit Margin for this corporation currently stands at 0.53% with Operating Profit Margin at -0.52%, Pretax Profit Margin comes in at -0.54%, and Net Profit Margin reading is -0.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.46 and Total Capital is -0.59. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.95 points at the first support level, and at 4.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.58, and for the 2nd resistance point, it is at 5.86.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] is 4.66. As well, the Quick Ratio is 4.66, while the Cash Ratio is 1.07. Considering the valuation of this stock, the price to sales ratio is 1.21, the price to book ratio is 1.38.
Transactions by insiders
Recent insider trading involved Klee Justin B., Co-Chief Executive Officer, that happened on Sep 30 ’24 when 18589.0 shares were sold. Co-Chief Executive Officer, Cohen Joshua B completed a deal on Sep 30 ’24 to sell 18589.0 shares. Meanwhile, Chief Medical Officer Bedrosian Camille L sold 11442.0 shares on Sep 30 ’24.
